Quantum BioPharma Advances Patented LUCID-MS for Multiple Sclerosis; Expands Wellness Pipeline with unbuzzd
QNTM•Quantum BioPharma’s Lucid Psycheceuticals is advancing LUCID-MS, a patented new chemical entity targeting multiple sclerosis, addressing unmet needs in mobility and function. The company has also expanded into consumer wellness by partnering with unbuzzd, a clinically validated alcohol metabolism accelerator designed to reduce sobriety time.
1. Therapeutic Focus on Neurological Disease
Quantum BioPharma is addressing the rising burden of neurodegenerative disorders by advancing therapies that protect neurons and preserve brain function, moving beyond symptom management to biological disease modification.
2. LUCID-MS Development for Multiple Sclerosis
Lucid Psycheceuticals Inc. is advancing LUCID-MS, a patented new chemical entity designed to slow progression and improve mobility in multiple sclerosis patients, targeting an unmet need in functional restoration.
3. Expansion into Alcohol Health Market
The company has partnered with unbuzzd to commercialize a clinically validated alcohol metabolism accelerator, aiming to shorten sobriety time and tap into the consumer wellness segment.
4. Strategic Diversification Strategy
By combining a novel neurological pipeline with consumer-ready alcohol health products, Quantum BioPharma aims to create multiple revenue streams and mitigate risks associated with single-market dependency.
